SCHEMBL13699366

SCHEMBL13699366

CC1CCC(Oc2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
CASP3 P42574 1/20 0.60
SENP8 Q96LD8 1/20 0.60
SENP6 Q9GZR1 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
EPHX2 P34913 14/20 0.58
FAAH O00519 4/20 0.55
PARP10 Q53GL7 1/20 0.51
SRD5A1 P18405 1/20 0.51
USP2 O75604 1/20 0.50
SRD5A2 P31213 1/20 0.50
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17190314 0.95 ALDH1A1 (0.55) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL22563077 0.92 EPHX2 (0.63) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL1977190 0.91 ALDH1A1 (0.70) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL3454901 0.86 SMN1; SMN2 (0.54) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL3453265 0.86 SMN1; SMN2 (0.54) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL13266897 0.86 ALDH1A1 (0.64) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL1028676 0.84 EPHX2 (0.68) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL11755572 0.84 PARP10 (0.71) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL10188548 0.83 ALDH1A1 (0.57) ALDH1A1LMNACASP3SENP8SENP6
SCHEMBL9640923 0.83 HRH1 (0.43) EPHX2PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R ALDH1A1 4542/4885LMNA 2227/4885CASP3 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.